Kalbe Farma Targets Optimal Performance in 2026 Through Strategic Implementation

Positive Growth Prospects for 2026

PT Kalbe Farma Tbk (KLBF), a leading Indonesian pharmaceutical company, is optimistic about achieving positive growth prospects in 2026. The company's management is confident that their strategic initiatives across various business segments will drive performance improvement. As of the end of 2025, Kalbe Farma remains committed to achieving its performance targets through sustained strategic implementation.

Strong 2025 Performance Foundation

Kalbe Farma's confidence in its 2026 prospects is built on a strong foundation of performance in 2025. The company is on track to achieve its sales growth target of 6%-8% for the year, driven by growth across almost all business lines. Key contributors to this growth include the prescription drugs segment, health products division, and the distribution & logistics business. This broad-based growth across multiple segments indicates a robust business model and effective strategic execution.

Strategic Focus Areas

The company's strategic initiatives are focused on four main business segments: prescription drugs, health products, nutrition, and distribution & logistics. By maintaining continuity in these strategic areas, Kalbe Farma aims to sustain its growth momentum into 2026. The management's confidence is based on the successful implementation of these strategies throughout 2025, positioning the company well for future growth.

Management's Outlook

Head of External & Stakeholders Relation at Kalbe Farma, Hari Nugroho, expressed the company's optimism about achieving its growth targets. He highlighted that the growth is driven by nearly all business lines, including prescription drugs, health products, and distribution & logistics. This comprehensive growth across various segments provides a solid foundation for the company's positive outlook for 2026.